Company Overview and News
TORONTO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) is pleased to announce the appointment of Chris Stewart, P.Eng., as the President and Chief Operating Officer (COO) effective September 1st, 2018. Chris replaces Xavier Ochoa who resigned as of July 13, 2018 to pursue an opportunity closer to his home and family in South America.
LSG BLT KGI MUX TSRMF BHPBF KGI.DB.A KGI.DB MUX.RTWI BHP LSG BBL BHP TML MUX BHPLF KL
VANCOUVER, British Columbia, July 18, 2018 (GLOBE NEWSWIRE) -- Group Ten Metals Inc. (TSX-V:PGE) (US OTC:PGEZF) (FSE:5D32) (the “Company” or “Group Ten”) is pleased to provide an update on the Company’s Black Lake-Drayton gold project, located in the Rainy River district of Northwest Ontario, Canada, including the completion of all outstanding earn-in requirements on two of the claim blocks. The Ontario asset complements Group Ten’s core Stillwater West project with a large and highly prospective land position which is strategically located beside advanced-stage projects in a world-class high-grade gold district.
DCGCF PGE NGD PGEZF TSRMF NGDAF NCPCF TML FFMGF NGD
TORONTO, July 09, 2018 (GLOBE NEWSWIRE) -- Sandy Lake Gold Inc. (the”Company” or “SLG”) (TSX-V:SLAU) is pleased to announce a partial award in the Arbitration Proceedings with Treasury Metals Inc. (TSX:TML) formerly Goldeye Explorations Limited (“Goldeye”) (see Treasury Metals press release dated July 11, 2016 available at SEDAR.com).
TSRMF GGY GEYEF TML
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to TSX:TML / Treasury Metals Inc. on message board site Silicon Investor.